Article
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
Molecular cancer therapeutics - 1 Mar 2020
Krook Melanie A, Lenyo Alexandria, Wilberding Max, Barker Hannah, Dantuono Mikayla, Bailey Kelly M, Chen Hui-Zi, Reeser Julie W, Wing Michele R, Miya Jharna, Samorodnitsky Eric, Smith Amy M, Dao Thuy, Martin Dorrelyn M, Ciombor Kristen K, Hays John, Freud Aharon G, Roychowdhury Sameek
Abstract excerpt
The fibroblast growth factor receptor (FGFR) signaling pathway is aberrantly activated in approximately 15% to 20% of patients with intrahepatic cholangiocarcinoma. Currently, several FGFR kinase inhibitors are being assessed in clinical trials for patients with FGFR-altered cholangiocarcinoma. Despite evidence of initial responses and disease control, virtually all patients eventually develop acquired...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.